Psyched: MDMA Therapy Advances With FDA, Alternatives For Alcohol Addiction, Prince Harry In The Spotlight And More

MDMA Therapy For PTSD Nearing Legalization In U.S. And Worldwide, MAPS Releases Promising Data

MAPS Public Benefit Corporation shared positive topline results from an observational follow-up of its two Phase 3 studies on the long-term safety and efficacy of MDMA-assisted therapy for PTSD. 

The findings show participants held a durable response within at least six months and in some cases a year or more, post-treatment with MDMA-assisted therapy.

"These results are consistent with previously published Phase 2 data demonstrating the sustained effect of MDMA-assisted therapy at least 12 months following treatment and suggest the acute treatment effect could last even longer," said MAPS PBC’s CEO, Amy Emerson.

Keep reading HERE.

UK-Based Approach To Alcohol Addiction: 5-MeO-DMT Candidate Moves To Phase 2 Clinical Stage

Clinical-stage private biotech company Beckley Psytech Ltd. has initiated a Phase 2a clinical study on its synthetic formulation of 5-MeO-DMT for the treatment of Alcohol Use Disorder (AUD) and will soon begin patient enrollment. 

CEO ‍Cosmo Feilding Mellen said the company’s aim to treat substance use disorders has led them to “the rigorous scientific investigation” on how short-acting formulations such as BPL-003 might address and reduce the burden that conditions like alcohol use disorder have on individuals, society and healthcare systems.

Keep reading HERE.

Prince Harry's Troubles: Deportation Demand Over Drug Use And Exclusion From Daddy's Coronation Plans

A conservative group is calling for the deportation of Prince Harry over his admissions of past drug use, including cocaine, cannabis and ayahuasca in his autobiography, "Spare."

Though applicants for U.S. visas are typically asked about previous drug use, visa records are considered confidential and legal experts say they’re uncertain whether Harry's past drug use would threaten his visa status. 

Keep reading HERE.

The Milestone Round

Each week, Benzinga learns about new clinical trials, compounds and potential treatments:

• Psycheceutical Bioscience Inc BWVI’s ketamine topical cream has attracted MAPS founder Rick Doblin’s attention, who said it could become an adjunct treatment for PTSD together with MDMA therapy. 

• In Congress, a bipartisan letter intends to further push for the inclusion of active service members in psychedelics-assisted therapy studies.

• An Uruguayan lawmaker has introduced a bill aiming to legalize natural psychedelics for those with a medical prescription.

• Read the first part of a one-on-one series with the creator of a psychedelics training aiming to decolonize and destigmatize the space’s practices.

• Learn about Angermayer’s “continued belief” in the sector and in ATAI Life Sciences NV ATAI, and psychiatrist Dr. Julie Holland’s view of cannabis as a “minor-league psychedelic”

• From 'shrooms to stars, check out the Super Mario Bros’ secret drug culture.

Here’s a bit of what you can expect from our extraordinary Psychedelics Capital Conference taking place in Miami in just a few days.

See Also: Last Week's Edition Of 'Psyched'

Psychedelics ETF Weekly Performance April 3-6:

AdvisorShares Psychedelics ETF PSIL opened Monday, April 3, at $1.83, slightly over the prior week’s opening at $1.80. After the week’s lowest point at $1.76 on Wed. April 5, it closed at $1.78 on Thursday, April 6, lower than prior closing at $1.87 on Friday, March 31.

For this ETF, the yearly price range is set between $4.35 and $1.70.

Benzinga’s PCC!

Benzinga’s Psychedelics Capital Conference is almost here: April 13 at the Fontainebleau Miami Beach Hotel will be the place to set up deals, raise money, meet investors and key partners and learn about the most pressing topics from the industry’s greatest.

Get your tickets NOW!